4/A: Janux Therapeutics Director Hernday Corrects Form 4 Filing, Reports RSU and Stock Option Grants

Natasha Hernday, a director at Janux Therapeutics, filed an amended Form 4 to correct the number of RSUs and shares subject to a stock option granted on July 19, 2024.

Summary

• Natasha Hernday, a director of Janux Therapeutics, Inc. [JANX], filed an amended Form 4 with the SEC.
• The amendment corrects a previous filing made on July 22, 2024, regarding transactions on July 19, 2024.
• The corrected filing reports the grant of 1,231 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Janux Therapeutics common stock.
• These RSUs will vest in full on July 19, 2025, contingent upon Hernday's continuous service.
• The filing also reports the grant of a stock option to purchase 4,111 shares of common stock at an exercise price of $44.68.
• The shares subject to the option will vest in twelve equal monthly installments over one year, also subject to continuous service.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The sentiment is neutral as it simply reports grants of equity compensation.

Positives

• The grant of RSUs and stock options could incentivize the director to work towards the long-term success of the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• Shareholders are informed about changes in insider ownership.
• The director is incentivized through equity compensation.

Key Dates